These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 35462410

  • 1. Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma.
    Nazha B, Zhuang TZ, Dada HI, Drusbosky LM, Brown JT, Ravindranathan D, Carthon BC, Kucuk O, Goldman J, Master VA, Bilen MA.
    Oncologist; 2022 Jun 08; 27(6):462-468. PubMed ID: 35462410
    [Abstract] [Full Text] [Related]

  • 2. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
    Shaib WL, Zakka K, Staley C, Roberts A, Akce M, Wu C, Alese OB, El-Rayes BF.
    Oncologist; 2020 May 08; 25(5):414-421. PubMed ID: 31784493
    [Abstract] [Full Text] [Related]

  • 3. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
    Zugazagoitia J, Ramos I, Trigo JM, Palka M, Gómez-Rueda A, Jantus-Lewintre E, Camps C, Isla D, Iranzo P, Ponce-Aix S, García-Campelo R, Provencio M, Franco F, Bernabé R, Juan-Vidal O, Felip E, de Castro J, Sanchez-Torres JM, Faul I, Lanman RB, Garrido P, Paz-Ares L.
    Ann Oncol; 2019 Feb 01; 30(2):290-296. PubMed ID: 30535340
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA.
    Xu J, Qu S, Sun N, Zhang W, Zhang J, Song Q, Lin M, Gao W, Zheng Q, Han M, Na C, Xu R, Chang X, Yang X, Huang J.
    J Clin Pathol; 2021 May 01; 74(5):314-320. PubMed ID: 32817175
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
    Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O.
    Oncologist; 2020 Apr 01; 25(4):327-333. PubMed ID: 32297439
    [Abstract] [Full Text] [Related]

  • 7. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R, Othman T, Chen C, Sandhu J, Ouyang C, Fakih M.
    Oncologist; 2020 Mar 01; 25(3):235-243. PubMed ID: 32162812
    [Abstract] [Full Text] [Related]

  • 8. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y, Zhang F, Yuan P, Guo L, Jianming Y, He J.
    Thorac Cancer; 2020 Jun 01; 11(6):1503-1511. PubMed ID: 32285618
    [Abstract] [Full Text] [Related]

  • 9. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS, Fang HY, Hung YC, Ke TW, Chang CM, Liu TY, Chen YC, Chao DS, Huang HY, Chang JG.
    J Cancer Res Clin Oncol; 2018 Nov 01; 144(11):2167-2175. PubMed ID: 30203147
    [Abstract] [Full Text] [Related]

  • 10. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
    Xi Y, Bai Z, Gao S, Guo J, Zhang Z, Zhang H, Qu L, Xu B, Wang W, Shan G, Cui W, Bai W, Ji X.
    J Cancer Res Clin Oncol; 2023 Sep 01; 149(11):8573-8580. PubMed ID: 37186065
    [Abstract] [Full Text] [Related]

  • 11. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.
    Ikeda S, Tsigelny IF, Skjevik ÅA, Kono Y, Mendler M, Kuo A, Sicklick JK, Heestand G, Banks KC, Talasaz A, Lanman RB, Lippman S, Kurzrock R.
    Oncologist; 2018 May 01; 23(5):586-593. PubMed ID: 29487225
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G, Kosirorek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Kasi PM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, Bekaii-Saab TS.
    Oncologist; 2021 Jul 01; 26(7):569-578. PubMed ID: 33555095
    [Abstract] [Full Text] [Related]

  • 14. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Husain H, Reckamp KL, Koczywas M, Massarelli E, Bild AH, Salgia R.
    Chest; 2021 Sep 01; 160(3):1095-1107. PubMed ID: 33878340
    [Abstract] [Full Text] [Related]

  • 15. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
    Ross JS, Wang K, Rand JV, Gay L, Presta MJ, Sheehan CE, Ali SM, Elvin JA, Labrecque E, Hiemstra C, Buell J, Otto GA, Yelensky R, Lipson D, Morosini D, Chmielecki J, Miller VA, Stephens PJ.
    J Clin Pathol; 2014 Nov 01; 67(11):968-73. PubMed ID: 25078331
    [Abstract] [Full Text] [Related]

  • 16. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
    Wang HY, Ho CC, Lin YT, Liao WY, Chen CY, Shih JY, Yu CJ.
    JCO Precis Oncol; 2024 Jan 01; 8():e2300314. PubMed ID: 38190582
    [Abstract] [Full Text] [Related]

  • 17. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL.
    Clin Cancer Res; 2016 Dec 01; 22(23):5772-5782. PubMed ID: 27601595
    [Abstract] [Full Text] [Related]

  • 18. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M, Qi C, Wang Z, Chen H, Zhao X, Zhang X, Zhou Y, Gao C, Bai Y, Jia S, Ji J.
    J Mol Med (Berl); 2021 Sep 01; 99(9):1311-1321. PubMed ID: 34057552
    [Abstract] [Full Text] [Related]

  • 19. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.
    Lam VK, Tran HT, Banks KC, Lanman RB, Rinsurongkawong W, Peled N, Lewis J, Lee JJ, Roth J, Roarty EB, Swisher S, Talasaz A, Futreal PA, Papadimitrakopoulou V, Heymach JV, Zhang J.
    Clin Lung Cancer; 2019 Jan 01; 20(1):30-36.e3. PubMed ID: 30279110
    [Abstract] [Full Text] [Related]

  • 20. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
    Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, Nanda I, Weigand I, Gehrig A, Steinhauer S, Riemens RJM, Rosenwald A, Müller CR, Kroiss M, Rost S, Fassnacht M, Ronchi CL.
    J Clin Endocrinol Metab; 2018 Dec 01; 103(12):4511-4523. PubMed ID: 30113656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.